ArticleCureus2024
Use of Magtrace as an Alternative Approach in Staging the Axilla in Early-Stage Breast Cancer: A Single-Center Experience.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dose Comparison (1 mL versus 2 mL) of Superparamagnetic Tracer for Sentinel Node Biopsy in Early Breast Cancer: Real-World Analysis from 456 Patients.Breast care (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The sentinel lymph node biopsy (SLNB) is the standard method used to determine the stage of breast cancer in patients with no clinical signs of axillary involvement. The current gold standard for the intraoperative assessment of the axilla involves the use of dual radioisotope and patent blue dye. However, researchers have been studying the use of superparamagnetic iron oxide Magtrace® (Endomagnetics Limited, Cambridge, United Kingdom) agents as an alternative to overcome the limitations of the standard SLNB technique. Aim The objective of this study was to assess the potential equivalency of the new SentiMag® (Endomagnetics Limited, Cambridge, United Kingdom) technique compared to the gold standard. The primary endpoints included the detection rate per patient and the number of lymph nodes retrieved. Materials and methods A single-center retrospective study was done in the Rotherham NHS Foundation Trust, UK, for patients who underwent SLNB from October 2021 to January 2022. Sixty patients were randomly selected and assigned into two arms: Magtrace and technetium-99m (99mTc). Categorical variables were compared using Fisher's exact test. Student's t-test was performed to compare continuous variables. Results There was a higher incidence of axillary seroma observed in the group of patients who underwent the Magtrace procedure. The average duration of the surgical procedure was longer for patients in the Magtrace arm compared to those in the 99mTc arm. The detection rate of SLNB was higher in the group of patients who received 99mTc. Both groups had a similar number of lymph nodes retrieved during the procedure. The length of hospital stay was comparable between the Magtrace and 99mTc groups. Conclusions Magtrace shows comparable practicality, surgical implementation, and risk of complications to standard practices. Additionally, it offers a potential cost benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.